Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of new combinations of treatments, including novel drugs and standard therapies, for patients with advanced or metastatic non-small cell lung cancer NSCLC. This multicenter, open-label study focuses on participants with stage IV NSCLC, specifically assessing combinations involving rilvegostomig with platinum-based chemotherapy and with or without ramucirumab. The study includes a sub-study with safety and dose expansion phases to identify the recommended dose and assess treatment activity. Participants with squamous and non-squamous NSCLC will receive intravenous infusions of rilvegostomig combined with standard chemotherapy drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel. Some participants will also receive ramucirumab as part of their treatment. The sub-study consists of a Part A safety run-in to evaluate dose levels and a Part B expansion phase to further study the treatments. Participants are randomized into different treatment arms depending on their cancer histology. During the study, participants will undergo monitoring for adverse events, dose-limiting toxicities, and tumor response over approximately 46 months. Assessments include measuring objective response, duration and time to response, disease control, progression-free survival, overall survival, and various blood drug concentration parameters. Tumor tissue samples are required for evaluation, and safety and tolerability are closely monitored throughout the treatment period.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effects of the drug EYU688 compared with a placebo in adults aged 18 to 60 who have dengue fever. This study aims to understand how EYU688 influences dengue viral load, fever clearance time, and clinical symptoms. It is a phase 2 randomized, participant- and investigator-blinded, placebo-controlled trial with two parallel cohorts differing by pharmacokinetic sampling schedules. Participants will receive EYU688 or a matching placebo orally. The study includes two cohorts running simultaneously one with intensive pharmacokinetic sampling and one with sparse sampling, to assess the drugs behavior in the body. Treatment is administered during the initial days following fever onset, with careful monitoring of viral load and clinical signs. Throughout the study, participants will undergo regular assessments including viral load measurements, fever monitoring, clinical symptom evaluations, and laboratory tests such as blood counts and liver enzyme levels. Safety monitoring for adverse events will continue through Day 35. The primary outcome is reduction in viral load at 48 hours after treatment start. The total trial period includes follow-up until Day 35, with ongoing evaluation of clinical recovery and safety.
Actively Recruiting
This research evaluates the long-term safety of asciminib treatment in patients with Philadelphia chromosome-positive chronic myelogenous leukemia CML or acute lymphoblastic leukemia ALL who have completed a prior Novartis-sponsored asciminib study. It is designed to provide continued treatment for participants who, as judged by their investigator, would benefit from ongoing therapy but cannot access it outside the trial. This open-label, multi-center, global roll-over study focuses on assessing safety over an extended period. Participants receive asciminib or other related drugs such as imatinib, nilotinib, bosutinib, or dasatinib, either alone or in combination, based on their previous study treatments. Dosing varies with the specific drug for example, asciminib is taken orally once or twice daily, sometimes in fasting state, and pediatric participants receive a body weight-adjusted dose of asciminib granules. The study includes groups continuing their previous treatment, some switching from bosutinib or dasatinib to asciminib, and combinations with other tyrosine kinase inhibitors. Participants are monitored for adverse events and serious adverse events over eight years as the primary safety outcome. Secondary outcomes include clinical benefit assessments by investigators. During the study, participants undergo scheduled visits, treatment adherence tracking, and safety monitoring. The study spans from August 2022 to August 2030, allowing long-term observation of treatment effects and safety in this patient population.
Actively Recruiting
Researchers are evaluating AZD0901, an antibody-drug conjugate, for its safety, tolerability, effectiveness, how the body processes it, and immune response in participants with advanced solid tumors that express Claudin 18.2. The study focuses on locally advanced unresectable or metastatic tumors and consists of different substudies targeting gastric esophageal cancer, pancreatic cancer, and biliary tract cancer. The study includes three substudies Substudy 1 tests AZD0901 alone in advanced gastric or gastroesophageal junction cancer with two randomized treatment arms. Substudy 2 has a safety run-in and dose expansion to assess AZD0901 combined with chemotherapy in pancreatic ductal adenocarcinoma. Substudy 3 evaluates AZD0901 alone in biliary tract cancer. Treatments are given via intravenous infusion, and participants receive either monotherapy or combination therapy depending on their group. Participants will undergo screening and receive regular assessments including physical exams, vital signs, ECGs, laboratory tests, and imaging to monitor tumor response and safety. Researchers will track adverse events, response rates, survival, and drug levels in the blood over approximately two years. Follow-up for safety continues for 90 days after stopping treatment. The study aims to provide detailed information on AZD0901s effects and side effects in these cancers.
Actively Recruiting
Researchers are evaluating the safety and tolerability of trastuzumab deruxtecan T-DXd combined with immunotherapy agents, with or without chemotherapy, in patients who have HER2 over-expressing non-small cell lung cancer NSCLC. This phase Ib study focuses on advanced or metastatic non-squamous NSCLC patients, aiming to understand optimal dosing and safety profiles. The study is sponsored by AstraZeneca and includes multiple study parts to explore different drug combinations and regimens. The trial includes several parts Part 1 involved dose escalation of T-DXd with durvalumab plus cisplatin, carboplatin, or pemetrexed Parts 3, 4, and 5 assess combinations of T-DXd with volrustomig or rilvegostomig, with or without carboplatin, in various dosing schedules. Patients receive the study drugs as intravenous infusions. Some parts involve randomization between arms with or without carboplatin, focusing on dose optimization in first-line treatment settings. Enrollment in some parts is closed, while others continue to explore safety and efficacy. Participants undergo regular assessments including tumor measurements by RECIST 1.1, organ and bone marrow function tests, and monitoring of adverse events for about 20 months. The study measures safety outcomes like frequency of adverse events and serious adverse events, and secondary outcomes such as response rate, duration of response, disease control, progression-free survival, overall survival, and pharmacokinetics of the drugs. Immunogenicity of the treatments is also evaluated. Participants must have measurable disease and meet performance status criteria, with follow-up to assess treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness of saruparib AZD5305 combined with camizestrant compared to physicians choice of CDK46 inhibitors plus endocrine therapy in patients with BRCA1, BRCA2, or PALB2 mutated, hormone receptor-positive, HER2-negative advanced breast cancer. This phase III study aims to determine which treatment better controls disease progression in this specific patient population. Participants will be randomly assigned to one of four treatment groups saruparib plus camizestrant physicians choice CDK46 inhibitor plus endocrine therapy physicians choice CDK46 inhibitor plus camizestrant or saruparib plus physicians choice endocrine therapy. Treatments are given orally or by injection as appropriate and will continue until the disease progresses, unacceptable side effects occur, or participants choose to stop treatment. During the study, participants will have regular assessments to evaluate disease progression, survival, response to treatment, and quality of life. Researchers will monitor drug levels in the blood and collect tissue samples to support diagnostic development. The study may last up to several years, with ongoing safety and efficacy evaluations to understand the impact of these treatments on advanced breast cancer.
1-10 of 14
1